NFATc1-IN-1
目录号 : GC69552NFATc1-IN-1 (compound A04) 一种是 RANKL- 诱导的破骨细胞 (osteoclast) 形成的有效抑制剂，其 IC50 为 1.57 μM。NFATc1-IN-1 通过降低 RANKL 诱导的 NFATc1 核转位，显示抗破骨细胞 (anti-osteoclastogenic) 作用。NFATc1-IN-1 可用于破骨疾病的研究。
Cas No.:1912422-56-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research[1].
NFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption[1].
NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1[1].
Cell Viability Assay[1]
| Cell Line: | Osteoclast precursor RAW 264.7 cells |
| Concentration: | 0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM |
| Incubation Time: | 4 days |
| Result: | Markedly reduced the number and size of red TRAP-positive multinucleated osteoclasts at concentrations of 1.5, 2.0, and 2.5 μM. Significantly inhibited formation of osteoclasts in a dose-dependent manner (at 1.5, 2.0 and 2.5 μM), while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM. |
Immunofluorescence[1]
| Cell Line: | RAW264.7 cells |
| Concentration: | 1.5 or 2.5 μM |
| Incubation Time: | 24 h |
| Result: | Blocked NFATc1 nuclear translocation and decreased the level of NFATc1. |
[1]. Chen CL, et al. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem. 2016 Jul 19;117:70-84.
| Cas No. | 1912422-56-0 | SDF | Download SDF |
| 分子式 | C13H8F2INO2 | 分子量 | 375.11 |
| 溶解度 | DMSO : 125 mg/mL (333.24 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6659 mL | 13.3294 mL | 26.6588 mL |
| 5 mM | 0.5332 mL | 2.6659 mL | 5.3318 mL |
| 10 mM | 0.2666 mL | 1.3329 mL | 2.6659 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet